12 Dec 2021
ASH 2021: Preliminary Results from a Phase I Study of HMPL-523, a Selective, Oral Syk Inhibitor, in Patients with Relapsed or Refractory Lymphoma.
THE LANCET :
FRESCO-2, a global Phase III study of fruquintinib in refractory metastatic colorectal cancer
Learn More
THE LANCET HAEMATOLOGY:
ESLIM-01 Phase III Study: Sovleplenib for primary immune thrombocytopenia patients in China
Learn More
THE LANCET Respiratory Medicine
Savolitinib Phase IIIb confirmatory study in treatment-naive METex14 NSCLC patients in China
Learn More
2024 Full Year Financial Results
Learn More
Latest News
11 Jan 2024HUTCHMED Announces NDA Acceptance in China for Sovleplenib for the Treatment of Primary Immune Thrombocytopenia with Priority Review StatusRead more 13 Dec 2023HUTCHMED Announces Continued Inclusion of ELUNATE® (fruquintinib) and SULANDA® (surufatinib) in the National Reimbursement Drug List in China at Current TermsRead more 13 Dec 2023HUTCHMED Announces that it has Completed Enrollment of a Phase II/III Trial of Fruquintinib in Combination with Sintilimab for Advanced Renal Cell Carcinoma in ChinaRead more
1 Dec 2023HUTCHMED Highlights Clinical Data to be Presented at 2023 ESMO Asia and ESMO Immuno-Oncology CongressesRead more 9 Nov 2023HUTCHMED Announces that Takeda Receives U.S. FDA Approval of FRUZAQLA™ (fruquintinib) for Previously Treated Metastatic Colorectal CancerRead more 16 Oct 2023HUTCHMED Highlights Clinical Data to be Presented at ESMO Congress 2023Read more 29 Sep 2023HUTCHMED Announces Submission of New Drug Application for Fruquintinib for Previously Treated Metastatic Colorectal Cancer in JapanRead more See all
2000
FOUNDED
HCM
NASDAQ &
LONDON AIM
LONDON AIM
13
HKEX
>20
NOVEL DRUG CANDIDATES
CREATED BY IN-HOUSE
DISCOVERY ENGINE
CREATED BY IN-HOUSE
DISCOVERY ENGINE
4
APPROVED & MARKETED
PRODUCTS IN CHINA
PRODUCTS IN CHINA
1
APPROVED & MARKETED
PRODUCT IN THE US, EU & JAPAN
PRODUCT IN THE US, EU & JAPAN
~40
CLINICAL TRIALS WORLDWIDE
INCLUDING 13+ REGISTRATION STUDIES
INCLUDING 13+ REGISTRATION STUDIES
>150,000
PATIENTS TREATED BY
OUR NOVEL MEDICINES
OUR NOVEL MEDICINES
OUR SCIENCE
Our core research and development philosophy is to take a holistic approach and treat cancer and immunological diseases through multiple modalities and mechanisms. We have taken a science-focused approach to develop highly selective, potent and well-tolerated cancer therapies that are deliberately engineered to improve drug exposure and reduce off-target toxicities.
FOLLOW HUTCHMED ON SOCIAL MEDIA
